The First Four Years:
2013-2016

A compelling growth story. A strong investment. A rapidly advancing pipeline.

abbvie-first-four-years

Our Four Year Performance

Since our inception as AbbVie, we have built an industry-leading performer with a portfolio and pipeline of innovative medicines that raise the standard of care for serious diseases. We invite you to take a closer look at our performance over the past four years. For a complete look at our 2016 performance, our earnings press release is located here.

Robust and Productive Pipeline

We are committed to discovering new medicines that improve the standard of care for many serious diseases and have a strong late-stage pipeline across several therapeutic areas.

robust-pipeline
* Revenue from new oncology, virology and neuroscience products launched since 2013 totaled more than $3.6 billion in 2016.
robust-pipeline
* 2016 GAAP R&D investment of $4.37B, +53% over 2013 GAAP R&D investment of $2.86B

Pipeline Compounds

AbbVie has built a leading pipeline of late-stage investigational compounds to treat several serious diseases and conditions.  In total, we have more than 50 investigational programs in clinical development.

robust-pipeline

Strong Return on Capital

AbbVie’s revenue and earnings have grown each year since inception, enabling the company to raise its dividend by 60% and achieve a total return of 111.4%.*

robust-pipeline
* As of December 31, 2016

Emerging Strength in Oncology

AbbVie is committed to improving the lives of people affected by cancer and is developing a pipeline of investigational medicines that span 20 different types of solid tumors and blood cancers.

robust-pipeline

For Investor and Media Use Only - Not For Promotional Use